APO Research
Talk to an analyst

APO RESEARCH · REPORT

Postmenopausal Vaginal Atrophy (PVA) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Analysis and Forecast 2026-2032

20 December 2025191 pages

Choose your research edition.

Industry ResearchPostmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Postmenopausal Vaginal Atrophy (PVA) Therapeutics include Teva Pharmaceuticals, Pfizer, Shionogi & Co, Novo Nordisk, Endoceutics and Accord Healthcare, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Postmenopausal Vaginal Atrophy (PVA) Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Postmenopausal Vaginal Atrophy (PVA) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Postmenopausal Vaginal Atrophy (PVA) Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Postmenopausal Vaginal Atrophy (PVA) Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Company

Teva Pharmaceuticals

Pfizer

Shionogi & Co

Novo Nordisk

Endoceutics

Accord Healthcare

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Type

Drugs Treatment

Other Treatments

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Application

Hospital

Clinic

Others

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Postmenopausal Vaginal Atrophy (PVA) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Postmenopausal Vaginal Atrophy (PVA) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Postmenopausal Vaginal Atrophy (PVA) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Postmenopausal Vaginal Atrophy (PVA) Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Postmenopausal Vaginal Atrophy (PVA) Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Drugs Treatment Major Player Table 3. Other Treatments Major Player Table 4. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Others Major Player Table 8. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Trends Table 9. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Drivers Table 10. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Opportunities and Challenges Table 11. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Restraints Table 12. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Region (2021-2026) Table 15. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Region (2027-2032) Table 17. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Players (2021-2026) Table 19. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Key Players Headquarters & Area Served Table 21. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Players, Product Type & Application Table 22. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Type (2021-2026) Table 29. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Type (2027-2032) Table 30. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Application (2021-2026) Table 34. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Application (2027-2032) Table 35. Teva Pharmaceuticals Company Information Table 36. Teva Pharmaceuticals Business Overview Table 37. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 39. Teva Pharmaceuticals Recent Development Table 40. Pfizer Company Information Table 41. Pfizer Business Overview Table 42. Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 44. Pfizer Recent Development Table 45. Shionogi & Co Company Information Table 46. Shionogi & Co Business Overview Table 47. Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 49. Shionogi & Co Recent Development Table 50. Novo Nordisk Company Information Table 51. Novo Nordisk Business Overview Table 52. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 54. Novo Nordisk Recent Development Table 55. Endoceutics Company Information Table 56. Endoceutics Business Overview Table 57. Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 59. Endoceutics Recent Development Table 60. Accord Healthcare Company Information Table 61. Accord Healthcare Business Overview Table 62. Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 64. Accord Healthcare Recent Development Table 65. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 66. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 67. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 68. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 69. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 70. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 71. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 72. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 73. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 74. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 75. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 76. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 77. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 78. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 79. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 80. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 81. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 82. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 84. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 85. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 86. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 87. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 89. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 90. SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 91. SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 92. SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 93. SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 94. SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 96. SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Image Figure 2. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Drugs Treatment Image Figure 5. Other Treatments Image Figure 6. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Others Image Figure 11. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (US$ Million) & (2021-2032) Figure 12. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Type (2021-2032) Figure 19. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Application (2021-2032) Figure 22. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Type (2021-2032) Figure 24. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Application (2021-2032) Figure 25. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Country (2021-2032) Figure 26. United States Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Type (2021-2032) Figure 31. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Application (2021-2032) Figure 32. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Country (2021-2032) Figure 33. Germany Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Type (2021-2032) Figure 43. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Application (2021-2032) Figure 44. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Type (2021-2032) Figure 46. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Application (2021-2032) Figure 47. Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Region (2021-2032) Figure 48. Japan Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Type (2021-2032) Figure 56. SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Application (2021-2032) Figure 57. SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Country (2021-2032) Figure 58. Brazil Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Drugs Treatment
  • Other Treatments
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Teva Pharmaceuticals
  • Pfizer
  • Shionogi & Co
  • Novo Nordisk
  • Endoceutics
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Type
  3. 1.2.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Drugs Treatment
  5. 1.2.3 Other Treatments
  6. 1.3 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Application
  7. 1.3.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Dynamics
  1. 2.1 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Trends
  2. 2.2 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Drivers
  3. 2.3 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Growth Trends by Region
  3. 3.2.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Players
  2. 4.1.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Players, Product Type & Application
  8. 4.5 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Tier 1, Tier 2, and Tier 3
5 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Type
  1. 5.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Type (2021-2032)
6 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size by Application
  1. 6.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva Pharmaceuticals
  2. 7.1.1 Teva Pharmaceuticals Company Information
  3. 7.1.2 Teva Pharmaceuticals Business Overview
  4. 7.1.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  6. 7.1.5 Teva Pharmaceuticals Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 Shionogi & Co
  14. 7.3.1 Shionogi & Co Company Information
  15. 7.3.2 Shionogi & Co Business Overview
  16. 7.3.3 Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  18. 7.3.5 Shionogi & Co Recent Developments
  19. 7.4 Novo Nordisk
  20. 7.4.1 Novo Nordisk Company Information
  21. 7.4.2 Novo Nordisk Business Overview
  22. 7.4.3 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  24. 7.4.5 Novo Nordisk Recent Developments
  25. 7.5 Endoceutics
  26. 7.5.1 Endoceutics Company Information
  27. 7.5.2 Endoceutics Business Overview
  28. 7.5.3 Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  30. 7.5.5 Endoceutics Recent Developments
  31. 7.6 Accord Healthcare
  32. 7.6.1 Accord Healthcare Company Information
  33. 7.6.2 Accord Healthcare Business Overview
  34. 7.6.3 Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  36. 7.6.5 Accord Healthcare Recent Developments
8 North America
  1. 8.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (2021-2032)
  2. 8.2 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country
  11. 8.6.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country
  11. 9.6.1 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (2021-2032)
  2. 10.2 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country
  11. 11.6.1 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst